ACSL4 and breast cancer: (116) collected biopsy specimens from 199 breast cancer patients who underwent paclitaxel-cisplatin chemotherapy and found through rank tests and Cox proportional regression analysis that the expression of ACSL4 and the combination status of ACSL4/GPX4 can serve as independent predictive factors for pathological complete response, and ACSL4 expression is positively correlated with overall survival in breast cancer patients.